Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3244)	2/11/2021 12:48:26 AM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

Yes, Evkeeza is a rare disease drug and doesn't really address the question. Obviously any company that lacks an overseas sales organization will have an uphill climb trying to BUILD one from scratch at the same time as launching a drug. This is why deals like the ones Regeneron made, make sense. The only problem I'm seeing is that Sanofi isn't living up to its end of the bargain because they unexpectedly suck at it. Maybe their "success" in overpricing insulin created a mirage that made them look like an effective organization, I don't know.